Early Disease Activity or Clinical Response as Predictors of Long‐Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis

OBJECTIVE: Early identification of patients unlikely to achieve good long‐term disease control with anti–tumor necrosis factor therapy in axial spondyloarthritis (SpA) and psoriatic arthritis (PsA) is important for physicians following treat‐to‐target recommendations. Here we assess associations bet...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Arthritis Care Res (Hoboken)
Päätekijät: van der Heijde, D., Deodhar, A., Fleischmann, R., Mease, P. J., Rudwaleit, M., Nurminen, T., Davies, O.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2017
Aiheet:
Spondyloarthritis
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5518306/
https://ncbi.nlm.nih.gov/pubmed/27696727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acr.23092
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia